Keywords: Agennix, Talactoferrin, NSCLC, Ph III
Agennix plunges as talactoferrin fails in NSCLC Ph III trial
Article | 09 August 2012
Germany and USA-based drug discoverer Agennix (FSE: AGX) saw its shares plummet 74% to 0.49 euros after reporting disappointing results from a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
